参考文献/References:
[1] Grassi G,Mark A,Esler M. The sympathetic nervous system alterations in human hypertension[J]. Circ Res,2015,116(6):976-990.
[2] Myrvang H.Hypertension: The Symplicity of renal denervation for patients with treatment-refractory hypertension[J]. Nat R ev Nephrol,2011,7(2):64.
[3] Baik J,Seo S,Lee S,et al. Circular radio-frequency electrode with MEMS temperature sensors for laparoscopic renal sympathetic denervation[J]. IEEE Trans Biomed Eng,2022,69(1):256-264.
[4] Zhang Q,Tan Y,Wen X,et al. Involvement of neuropeptide Y within paraventricular nucleus in electroacupuncture inhibiting sympathetic activities in hypertensive rats[J]. Int J Hypertens,2022,2022:9990854.
[5] Lu Y,Hao R,Hu Y,et al. Harpagide alleviate neuronal apoptosis and blood-brain barrier leakage by inhibiting TLR4/MyD88/NF-κB signaling pathway in AngiotensinⅡ-induced microglial activation in vitro[J]. Chem B iol Interact,2021,348:109653.
[6] Forrester SJ,Booz GW,Sigmund CD,et al. Angiotensin Ⅱ signal transduction:an update on mechanisms of physiology and pathophysiology[J]. Physiol R ev,2018,98(3):1627-1738.
[7] Sherrod M,Davis DR,Zhou X,et al. Glial-specific ablation of angiotensinogen lowers arterial pressure in renin and angiotensinogen transgenic mice[J]. Am J Physiol Regul Integr Comp Physiol,2005,289(6):R1763-R1769.
[8] Crowley SD,Coffman TM.Recent advances involving the renin-angiotensin system[J]. Exp C ell Res,2012,318(9):1049-1056.
[9] Hilzendeger AM,Cassell MD,Davis DR,et al. Angiotensin type 1a receptors in the subfornical organ are required for deoxycorticosterone acetate-salt hypertension[J]. Hypertension,2013,61(3):716-722.
[10] Omboni S,Volpe M.Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors for the treatment of arterial hypertension and the role of olmesartan[J]. Adv Ther,2019,36(2):278-297.
[11] DiBona GF. Sympathetic nervous system and hypertension[J]. Hypertension ,2013,61(3):556-560.
[12] Dampney RA,Michelini LC,Li DP,et al. Regulation of sympathetic vasomotor activity by the hypothalamic paraventricular nucleus in normotensive and hypertensive states[J]. Am J Physiol Heart Circ Physiol,2018,315(5):H1200-H1214.
[13] Kang YM,Zhang AQ,Zhao XF,et al. Paraventricular nucleus corticotrophin releasing hormone contributes to sympathoexcitation via interaction with neurotransmitters in heart failure[J]. Basic Res C ardiol,2011,106(3):473-483.
[14] Li YF,Jackson KL,Stern JE,et al. Interaction between glutamate and GABA systems in the integration of sympathetic outflow by the paraventricular nucleus of the hypothalamus[J]. Am J Physiol Heart Circ P hysiol,2006,291(6):H2847-H2856.
[15] Ma H,Cui Z,Guo X,et al. Corticotropin-releasing factor potentiates glutamatergic input and excitability of presympathetic neurons in the hypothalamus in spontaneously hypertensive rats[J]. Neuropharmacology,2023,230:109506.
[16] Biancardi VC,Campos RR,Stern JE. Altered balance of gamma-aminobutyric acidergic and glutamatergic afferent inputs in rostral ventrolateral medulla-projecting neurons in the paraventricular nucleus of the hypothalamus of renovascular hypertensive rats[J]. J C omp Neurol,2010,518(5):567-585.
[17] Liu XJ,Yu XJ,Su YK,et al. Minocycline and pyrrolidine dithiocarbamate attenuate hypertension via suppressing activation of microglia in the hypothalamic paraventricular nucleus[J]. Tohoku J Exp Med,2023,259(2):163-172.
[18] Nayak D,Roth TL,McGavern DB. Microglia development and function[J]. Annu Rev Immunol,2014,32:367-402.
[19] Girard S,Brough D,Lopez-Castejon G,et al. Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices[J]. Glia,2013,61(5):813-824.
[20] Ma Y, Wang J, Wang Y,et al. The biphasic function of microglia in ischemic stroke[J]. Prog N eurobiol,2017,157:247-272.
[21] Mowry FE,Peaden SC,Stern JE,et al. TLR4 and AT1R mediate blood-brain barrier disruption,neuroinflammation,and autonomic dysfunction in spontaneously hypertensive rats[J]. Pharmacol Res,2021,174:105877.
[22] Kreutzberg GW. Microglia:a sensor for pathological events in the CNS[J]. Trends Neurosci,1996,19(8):312-318.
[23] Shi P,Diez-Freire C,Jun JY,et al. Brain microglial cytokines in neurogenic hypertension[J]. Hypertension,2010,56(2):297-303.
[24] Su Q,Qin DN,Wang FX,et al. Inhibition of reactive oxygen species in hypothalamic paraventricular nucleus attenuates the renin-angiotensin system and proinflammatory cytokines in hypertension[J]. Toxicol A ppl Pharmacol,2014,276(2):115-120.
[25] Lim KH,Staudt LM. Toll-like receptor signalling[J]. Nat R ev Immunol,2004,4(7):499-511.
[26] Caso JR,Pradillo JM,Hurtado O,et al. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke[J]. Circulation,2007,115(12):1599-1608.
[27] Wang K,You S,Hu H,et al. Effect of TLR4/MyD88/NF-kB axis in paraventricular nucleus on ventricular arrhythmias induced by sympathetic hyperexcitation in post-myocardial infarction rats[J]. J C ell M ol M ed,2022,26(10):2959-2971.
[28] Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease[J]. Nat R ev Immunol,2011,11(11):775-787.
[29] Lehnardt S,Massillon L, Follett P,et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway[J]. Proc Natl Acad Sci U S A,2003,100(14):8514-8519.
[30] Wolf G,Bohlender J,Bondeva T,et al. Angiotensin Ⅱ upregulates toll-like receptor 4 on mesangial cells[J]. J Am Soc Nephrol,2006,17(6):1585- 1593.
[31] Dasu MR,Riosvelasco AC,Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo[J]. Atherosclerosis,2009,202(1):76-83.
[32] Masson GS,Nair AR,Dange RB,et al. Toll-like receptor 4 promotes autonomic dysfunction,inflammation and microglia activation in the hypothalamic paraventricular nucleus:role of endoplasmic reticulum stress[J]. PLoS One,2015,10(3):e0122850.
[33] Burguillos MA,Deierborg T,Kavanagh E,et al. Caspase signalling controls microglia activation and neurotoxicity[J]. Nature,2011,472(7343):319-324.
[34] Gao HL,Yu XJ,Feng YQ,et al. Luteolin attenuates hypertension via inhibiting NF-κB-mediated inflammation and PI3K/Akt signaling pathway in the hypothalamic paraventricular nucleus[J]. Nutrients,2023,15(3):502.
[35] Dange RB,Agarwal D,Teruyama R,et al. Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension[J]. J Neuroinflammation,2015,12:31.
[36] Dange RB,Agarwal D,Masson GS,et al. Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin Ⅱ-induced hypertension[J]. Cardiovasc R es,2014,103(1):17-27.
[37] Wang N,Guo W,Liu T,et al. Toll-like receptors(TLR2 and TLR4) antagonist mitigates the onset of cerebral small vessel disease through PI3K/Akt/GSK3β pathway in stroke-prone renovascular hypertensive rats[J]. Biotechnol G enet E ng Rev,2023:1-21.
[38] Biancardi VC,Stranahan AM,Krause EG,et al. Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin Ⅱ-derived ROS production in the hypothalamic paraventricular nucleus[J]. Am J Physiol Heart Circ P hysiol,2016,310(3):H404-H415.
[39] Li HB,Li X,Huo CJ,et al. TLR4/MyD88/NF-κB signaling and PPAR-γ within the paraventricular nucleus are involved in the effects of telmisartan in hypertension[J]. Toxicol Appl P harmacol,2016,305:93-102.
[40] Qi J,Yu XJ,Fu LY,et al. Exercise training attenuates hypertension through TLR4/MyD88/NF-κB signaling in the hypothalamic paraventricular nucleus[J]. Front N eurosci,2019,13:1138.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(5):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(5):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(5):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(5):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(5):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(5):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]